|Security||CYTX / Cytori Therapeutics, Inc. (23283K105)|
|President and CEO||HEDRICK MARC H|
|Industry||Surgical and Medical Instruments and Apparatus|
|Institutional Shares||404,372 - 0.66%|
|Common Stock Shares Outstanding||61,600,000 shares (as of 2018-06-30)|
|Institutional Value||$ 554,000 USD|
CTYX / Connectyx Technologies Holdings Group, Inc.|
CYTXW / Cytori Therapeutics, Inc. Warrants
Institutional Stock Ownership and Shareholders
Cytori Therapeutics, Inc. (NASDAQ:CYTX) has 11 institutional investors and shareholders that have
filed 13D/G or 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 404,372 shares.
Largest shareholders include
BlackRock Institutional Trust Company, N.A., BlackRock Fund Advisors, Dimensional Fund Advisors Lp, Macquarie Group Ltd, FNY Partners Fund LP, BlackRock Investment Management, LLC, Ladenburg Thalmann Financial Services Inc, BlackRock Advisors LLC, Fny Investment Advisers, Llc, and Barclays Plc.
Cytori Therapeutics, Inc. (NASDAQ:CYTX) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.
|MACQUARIE GROUP LTD||0||40,182||0||29|
|PERKINS CAPITAL MANAGEMENT INC||2,071,106||0||-100.00||593||0||-100.00|
|SIMPLEX TRADING, LLC||Call||61||0||-100.00||0||0|
|BANK OF AMERICA CORP /DE/||718||0||-100.00||0||0|
|BlackRock Fund Advisors||33,449||44,201||32.14||68||67||-1.47|
|BlackRock Institutional Trust Company, N.A.||253,335||253,335||0.00||514||383||-25.49|
|Intellectus Partners, LLC||30,000||0||-100.00||9||0||-100.00|
|THOMPSON DAVIS & CO., INC.||34||0||-100.00||0||0|
|ROYAL BANK OF CANADA||3,231||0||-100.00||1||0||-100.00|
|Fny Investment Advisers, Llc||1,480||2|
|BlackRock Advisors LLC||2,594||2,594||0.00||5||4||-20.00|
|SUSQUEHANNA INTERNATIONAL GROUP, LLP||62,863||0||-100.00||18||0||-100.00|
|FNY Partners Fund LP||14,800||14,800||0.00||4||4||0.00|
|VANGUARD GROUP INC||606,749||0||-100.00||174||0||-100.00|
|HUDSON CANYON INVESTMENT COUNSELORS LLC||6,342||0||-100.00||2||0||-100.00|
|Alpha Omega Wealth Management LLC||534||0||-100.00||0||0|
|DEUTSCHE BANK AG\||92||0||-100.00||0||0|
|Manchester Capital Management LLC||28||0||-100.00||0||0|
|MetLife Securities, Inc||51||51||0.00||0||0|
|NORTHERN TRUST CORP||55,507||0||-100.00||16||0||-100.00|
|BLAIR WILLIAM & CO/IL||25,087||0||-100.00||7||0||-100.00|
|HighTower Advisors, LLC||15,934||0||-100.00||5||0||-100.00|
|Marathon Capital Management||11,335||0||-100.00||3||0||-100.00|
|Lee Financial CORP||282||0||-100.00||0||0|
|SUSQUEHANNA INTERNATIONAL GROUP, LLP||Call||46,000||0||-100.00||13||0||-100.00|
|Plante Moran Financial Advisors, LLC||5,000||0||-100.00||1||0||-100.00|
|GEODE CAPITAL MANAGEMENT, LLC||166,315||0||-100.00||47||0||-100.00|
|WELLS FARGO & COMPANY/MN||241||0||-100.00||0||0|
|Virtu Financial LLC||143,401||0||-100.00||41||0||-100.00|
|DIMENSIONAL FUND ADVISORS LP||0||40,990||0||59|
|Jefferies Group LLC||746,367||0||-100.00||214||0||-100.00|
|LADENBURG THALMANN FINANCIAL SERVICES INC||3,061||3,061||0.00||1||1||0.00|
|CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM||13,226||0||-100.00||4||0||-100.00|
|BlackRock Investment Management, LLC||3,531||3,531||0.00||7||5||-28.57|
|UBS Group AG||29,700||0||-100.00||8||0||-100.00|
|Advisor Group, Inc.||160||0||-100.00||0||0|
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Related News Stories
Cytori Therapeutics (CYTX - Free Report) announced that the FDA has granted Orphan Drug designation to its chemotherapy candidate, ATI-1123, for the treatment of small cell lung cancer (“SCLC”). (5-0)
Good afternoon, ladies and gentlemen. Welcome to the Cytori Therapeutics Second Quarter 2018 Earnings Results Call. At this time, all participants have been placed in a listen-only mode and the floor will be opened for your questions following the presentation. [Operator Instructions]
Note: ISR has a market cap of less than $100mn and trades below $1. These stocks are inherently risky, and we do not invest in such stocks. However, on Monday, on this news, the stock went above $1, which is when we covered it. (53-6)
Cytori Therapeutics, headquartered in San Diego, published data from its clinical trial of Adipose-Derived Regenerative Cells (ADRCs) in the journal Urology showing positive results.
Good afternoon, ladies and gentlemen. Welcome to Cytori Therapeutics First Quarter 2018 Earnings Results Call. At this time, all participants have been placed in a listen-only mode and the floor will be opened for questions following the presentation. [Operator Instructions] (25-1)
as of ET